Clinical Trial Update: Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update on lanreotide Autogel for symptomatic polycystic liver disease, covering Phase 2 and Phase 3, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Liver Disease

Drugs mentioned

• Lanreotide Autogel (lanreotide)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Polycystic Liver Disease | Phase 2, Phase 3 | Status: COMPLETED